Tenshi / InstaPill®’s proprietary Lyophilized Orally Disintegrating Tablets experts provide innovative solutions to expand the reach of your products and give you a competitive advantage. By leveraging the proprietary orally disintegrating tablet (ODT) technology, InstaPill® provides extensive support to extend your product’s life.
InstaPill® is a fast-dissolving, gelatin-free orally dissolving tablet (ODT) manufacturing platform offering the highest level of convenience to your patients. InstaPill® ODTs disperse in seconds without water and are effortless to swallow improving patient compliance. Utilizing versatile taste-masking tools, InstaPill® ODTs are pleasantly flavoured with no grittiness, increasing patient preference. InstaPill® ODT technology offers a novel delivery format for vaccines, and bioequivalent formulations of even combination products. Our expert team will design a patient centric InstaPill® formulation for your brand and assist with development and regulatory strategies to give a competitive advantage.
Learn moreAt InstaPill® our ODT technology can be applied across many different therapeutic areas to achieve a number of different formulation goals.
Helping you develop ODTs, we can facilitate brand lifecycle management by extending patents and improving formulations with novel delivery formats.
Improve convenience and compliance for your consumers with the rapid dissolve, gelatin-free ODTs to give you a competitive edge.
Our specialists help you design and develop patient-centric ODT formulations that improve the acceptability of your medicines to customers.
At InstaPill®, our team have extensive experience across formulation, scale-up and manufacturing. InstaPill® is an efficient CDMO partner with QbD and DoE principles for formulation and process development, and highly automated state-of-the-art commercial manufacturing facilities. Combining innovation and expertise with our ODT technology, InstaPill® develops lyophilised, gelatin-free ODTs and leverages proven taste masking, flavour optimisation approaches to improve the palatability of ODTs without altering the pharmacological parameters. With 5 filed dossiers of our own, our in-house regulatory and clinical expertise supports partners to manage Bio-Equivalence studies, eCTD production, regulatory filings and accelerated approval strategies for seamless market launch.
Find out more
